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Updated Method Guidelines for Systematic Reviews in
the Cochrane Collaboration Back Review Group
Maurits van Tulder, PhD,*†‡ Andrea Furlan, MD,‡ Claire Bombardier, MD, FRCP,‡§¶#
Lex Bouter, PhD,* and the Editorial Board of the Cochrane Collaboration Back Review Group
Study Design. Descriptive method guidelines.
Objectives. To help reviewers design, conduct, and
report reviews of trials in the field of back and neck pain.
Summary of Background Data. In 1997, the Cochrane
Collaboration Back Review Group published method
guidelines for systematic reviews. Since its publication,
new methodologic evidence emerged and more experi-
ence was acquired in conducting reviews.
Methods. All reviews and protocols of the Back Re-
view Group were assessed for compliance with the 1997
method guidelines. Also, the most recent version of the
Cochrane Handbook (4.1) was checked for new recom-
mendations. In addition, some important topics that were
not addressed in the 1997 method guidelines were in-
cluded (e.g., methods for qualitative analysis, reporting of
conclusions, and discussion of clinical relevance of the
results). In May 2002, preliminary results were presented
and discussed in a workshop. In two rounds, a list of all
possible recommendations and the final draft were circu-
lated for comments among the editors of the Back Review
Group.
Results. The recommendations are divided in five cat-
egories: literature search, inclusion criteria, methodologic
quality assessment, data extraction, and data analysis.
Each recommendation is classified in minimum criteria
and further guidance. Additional recommendations are
included regarding assessment of clinical relevance, and
reporting of results and conclusions.
Conclusions. Systematic reviews need to be con-
ducted as carefully as the trials they report and, to achieve
full impact, systematic reviews need to meet high meth-
odologic standards. [Key words: systematic reviews,
meta-analysis, Cochrane Collaboration, method guide-
lines, back pain, neck pain] Spine 2003;28:1290–1299
The current interest in evidence-based medicine has led
to an extensive increase in the publication of systematic
reviews. Recently, the QUOROM statement was devel-
oped to improve the standards for the report of system-
atic reviews.1 Several leading medical journals (e.g.,
BMJ, JAMA, Lancet) have adopted the QUORUM rec-
ommendations for the reporting of abstract, introduc-
tion, methods, results, and discussion sections of system-
atic reviews. However, it has been shown that many
reviews in the field of back pain are of low methodologic
quality and that their reports often lack essential
components.2,3
In 1997, the editorial board of the Cochrane Collab-
oration Back Review Group (BRG) published method
guidelines for systematic reviews in the field of spinal
disorders.4 These method guidelines addressed the main
steps in conducting a systematic review: literature search,
inclusion criteria, methodologic quality, data extraction,
and data analysis. The purpose of the method guidelines
was to offer guidance to researchers preparing, conduct-
ing, or reporting a systematic review and to readers eval-
uating these reviews. The guidelines were operational-
ized specifically for the field of back pain. They included
certain minimum criteria for which empirical evidence
existed that they are associated with bias in systematic
reviews or for which consensus existed among the edito-
rial board of the BRG that they are likely to be associated
with bias. In addition, further guidance was presented to
enhance the quality of systematic reviews.
The BRG was established in 1996 and did not have a
systematic review published in the Cochrane Library at
the time of publication of the method guidelines.5 At
present, 21 completed reviews and 7 protocols of various
treatments for spinal disorders are published in the Co-
chrane Library (issue #4, 2002). Many of these reviews
have a copublication in Spine (for more information,
visit www.cochrane.iwh.on.ca). Because new evidence
on review methodology has emerged since 1997 and the
BRG has acquired ample experience in preparing, con-
ducting, and reviewing systematic Cochrane reviews, it
seems necessary to update the 1997 method guidelines.
For example, the 1997 method guidelines included rec-
ommendations for quantitative (meta-)analysis. How-
ever, in many of the reviews within the BRG, the authors
refrained from statistical pooling or concluded that in-
sufficient data were provided to enable statistical pooling
and consequently conducted a qualitative analysis (or
best-evidence synthesis) for which no clear guidelines
were provided. Also, only a few reviews currently pub-
lished within the BRG include a discussion of the clinical
relevance of trial results. Lastly, the reporting of conclu-
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sions in reviews within the BRG varies widely. There-
fore, we decided to modify existing and add some new
recommendations in an update of the 1997 method
guidelines.
It should be emphasized that these guidelines are not a
“gold standard” but merely an indication of the current
“state-of-the-art” of review methods. The method guide-
lines are useful to plan, conduct, or evaluate other sys-
tematic reviews in the field of back pain within and out-
side the framework of the BRG. The usefulness of the
1997 method guidelines is reflected in the number of
citations in published scientific articles (n  63, Novem-
ber 10th, 2002).
Methods
In order to assess the need for an update, all reviews and pro-
tocols of the BRG were assessed for compliance with the 1997
method guidelines. Also, the most recent version of the Co-
chrane Handbook (4.1) was checked for new recommenda-
tions. In addition, the editorial board of the BRG recognized
that some important topics were not addressed in the 1997
method guidelines (e.g., methods for qualitative analysis, re-
porting of conclusions, and discussion of clinical relevance of
the results).
The compliance of the reviews and protocols with the min-
imum criteria and further guidance recommendations of the
1997 method guidelines is shown in Tables 1 and 2, respec-
tively. The Cochrane Library issue #4, 2002, contained 21
completed reviews and 7 protocols of the BRG.
In March 2002, a literature search was conducted in the
Cochrane Database of Methodology (from 1997–2002) and in
PubMed for articles dealing with methods of conducting a sys-
tematic review. A total of 584 titles and abstracts were
screened, and hard copies of selected papers were retrieved.
The recommendations were updated if new evidence was
found, and the latest relevant publications were included in the
references (even if the evidence did not change, we replaced
older references by more recent ones).
In May 2002, preliminary results were presented and dis-
cussed in a workshop at the Fifth International Forum for Pri-
mary Care Research in Low Back Pain involving members of
the BRG editorial board, (co)authors of reviews, and other
experts on low back pain research interested in systematic re-
view methodology. After the workshop, a list of all possible
recommendations, including all items of the 1997 method
guidelines plus additional items from the literature search, the
Cochrane Handbook, and experience with BRG reviews, was
circulated among the editors of the BRG. Each editor was asked
to decide if a specific recommendation should be included as a
minimum criterion or as further guidance, or if it should not be
included at all. Six of the eight editors participated in this pro-
cess. A final version of the updated method guidelines was
prepared and circulated among all BRG editors for comments.
Table 1. Comparison of the Minimum Criteria of the 1997 Cochrane Back Review Group Method Guidelines With the
Cochrane Handbook (Version 4.1) and Compliance of Cochrane Back Review Group Protocols and Reviews With These
Recommendations
Minimum Criteria Cochrane Handbook Protocols Review
Literature search
MEDLINE Yes 27/28 96%
EMBASE Yes 27/28 96%
Cochrane Library (CENTRAL) Yes 24/28 86%
Sensitive Search strategy by UK Cochrane Centre Yes 23/28 82%
Screening of references Yes 25/28 89%
Handsearch Cochrane Centre Baltimore No 0 0%
Personal communication with content experts Yes 17/28 61%
Inclusion criteria
Inclusion of randomized controlled trials Yes 28/28 100%
Description of participants by age Yes 23/28 82%
Description of participants by acute, subacute, chronic Yes 16/28 57%
Description of participants by localization of pain Yes 28/28 100%
Description of participants by type of symptoms Yes 23/28 82%
Explicit description of type of intervention Yes 26/28 93%
Explicit description of outcome measure Yes 28/28 100%
Symptoms as outcome Yes 27/28 96%
Overall improvement as outcome Yes 19/28 68%
Function as outcome Yes 26/28 93%
Well being as outcome Yes 20/28 71%
Disability as outcome Yes 22/28 79%
Methodological quality assessment
Assessment by at least 2 independent reviewers Yes 25/28 89%
Item: concealment of treatment allocation/randomization Yes 23/28 82%
Item: drop-out rate Yes 23/28 82%
Item: blinding of patients Yes 17/28 61%
Item: blinding of observers Yes 22/28 79%
Item: intention-to-treat analysis No 18/28 64%
Data extraction
Data extracted by at least 2 reviewers Yes 25/28 89%
Data analysis
Reason behind choice for quantitative or qualitative Yes 18/28 64%
Review
Explicit description of approach Yes 26/28 93%
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Method Guidelines
Literature Search
Minimum Criteria. Because one of the main principles of a
systematic review is to include all available evidence, the literature
search is the first and a very important step in conducting a sys-
tematic review. The starting point for the literature search is to
decide which articles should be retrieved, ensuring that as many
relevant trials as possible are identified. The search strategy should
relate directly to the research question(s) of the review at issue and
should be based on the inclusion criteria regarding study design,
participants, interventions, outcomes, and language (see Inclusion
Criteria section). A simple MEDLINE search is clearly insufficient,
because it has been shown that in general only approximately half
of the available randomized clinical trials (RCTs) will be identified
if the identification of RCTs solely depends on MEDLINE search-
es.6 It has been suggested that at least MEDLINE and EMBASE
must be used to ensure a comprehensive literature search, because
overlap between these databases is small.7,8 Especially in the field
of low back pain, EMBASE seems to retrieve more clinical trials
than MEDLINE.9
Therefore, we recommend the following as a minimum
search strategy:
1. A computer aided search of the MEDLINE and EMBASE
databases since their beginning. The highly sensitive search
strategies for retrieval of reports of controlled trials10 should
be run in conjunction with a specific search for spinal disorders
and the intervention at issue (see Appendix 1 and 2).
2. A search of the Cochrane Central Register of Controlled
Trials (Central) that is included in the latest issue of the
Cochrane Library.11
3. Screening references given in relevant systematic reviews
and identified RCTs.
4. Personal communication with content experts in the
field.12 It is to the discretion of the reviewers to identify who
the experts are on a specific topic.
We recommend that two reviewers independently apply the
inclusion criteria to select the potentially relevant trials from
the titles, abstracts, and key words of the references retrieved
by the literature search. We suggest pilot testing the inclusion
criteria on a sample of articles, including some considered to be
definitely eligible, some definitely not eligible, and some ques-
tionable.13 Articles for which disagreement exists and articles
for which title, abstract, and key words provide insufficient
information for a decision on selection should be obtained to
assess whether they meet the inclusion criteria. A consensus
method should be used to solve disagreements between the two
reviewers regarding the inclusion of studies. A third reviewer
should be consulted if disagreements are not resolved in the
consensus meeting.
Table 2. Comparison of the Further Guidance of the 1997 Cochrane Back Review Group Method Guidelines With the
Cochrane Handbook (Version 4.1), and Compliance of Cochrane Back Review Group Protocols and Reviews With
These Recommendations
Further Guidance Cochrane Handbook Protocol Review
Literature search
Specific database for intervention at issue Yes 23/28 82%
Handsearch key journals No 5/28 18%
Citation tracking (Science Citation Index) Yes 14/28 50%
Identification of trials by at least 2 reviewers Yes 24/28 86%
Pilot test inclusion criteria Yes 3/28 11%
Consensus method to solve disagreement Yes 23/28 82%
Inclusion criteria
Reason for inclusion of non-randomized trials Yes 5/19 26%
Inclusion of physical examination as outcome Yes 16/28 57%
Inclusion of other symptoms as outcome Yes 12/28 43%
No language restrictions No 17/28 61%
Reason for exclusion of non-English articles No 3/11* 27%
Methodological quality assessment
Assessment blinded for authors, institutions, journal Yes 6/28 21%
Assessment by content expert and non-expert Yes 2/28 7%
Pilot test of quality assessment Yes 7/28 25%
Consensus method to solve disagreement Yes 21/28 75%
Assessment of interobserver reliability Yes 13/28 46%
Use of recommended criteria list Yes 12/28 43%
Explicit operationalization of criteria Yes 12/28 43%
Data extraction
Extraction blinded for authors, institutions, journal Yes 5/28 18%
Use of standardized form Yes 17/28 61%
Pilot test the data extraction form Yes 4/28 14%
Consensus method to solve disagreements Yes 10/28 36%
Contact author for additional information Yes 13/28 46%
Data analysis
Explicit description of comparisons Yes 18/28 64%
Analysis of clinical heterogeneity Yes 16/28 57%
Statistical test for heterogeneity Yes 15/28 54%
Use of random effects model Yes 4/9† 44%
Subgroup analysis related to review objectives Yes 17/28 61%
* Eleven reviews/protocols excluded non-English language trials.
† Nine reviews included a meta-analysis.
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Further Guidance. Depending on the intervention at issue, if
available, a specific database should be searched; for example:
● Mantis (Manual Alternative and Natural Therapy Index
System; formerly Chirolars) for chiropractic intervention
(http://www.chiroaccess.com/MANTISAbout.html)
● Ciscom (Research Council for Complementary Medicine,
London, UK) for complementary medicine interventions
(http://www.rccm.org.uk/ciscom/CISCOM_intro.asp)
● Psyc INFO for psycho log i ca l i n t e rven t ions
(http://www.apa.org/psycinfo)
● PEDro (Physiotherapy Evidence Database) for physio-
therapy (http://ptwww.cchs.usyd.edu.au/pedro)
Citation tracking of the identified RCTs (use of Science Ci-
tation Index to search forward in time for subsequent articles
that have cited the identified RCTs) is recommended. The value
of using citation tracking has not yet been established, but it
may be especially useful to identify additional studies on topics
that are poorly indexed in MEDLINE and EMBASE.
Inclusion Criteria
Minimum Criteria
Study Design. Randomized clinical trials should be included.
Nonrandomized controlled clinical trials (CCTs) may be in-
cluded if there are less than five RCTs. If authors wish to extend
a systematic review beyond RCTs by also including observa-
tional studies, the reason for this should be outlined.
Participants. Participants of trials that will be included in
the systematic review should be defined explicitly in terms of
age, gender, duration of symptoms, localization of symptoms,
type of symptoms, and setting. It is especially recommended to
clearly report if patients with acute (less than 6 weeks), sub-
acute (6–12 weeks) and/or chronic (12 weeks or more) low
back pain are included.
Interventions. The type, intensity, frequency, and duration
of index interventions that will be included in the systematic
review should be explicitly described as well as the specific
comparison groups. (For example, spinal manipulation versus
placebo manipulation, spinal manipulation versus other active
interventions, or spinal manipulation versus no treatment.)
Outcomes. The outcome measures and instruments that will
be included in a systematic review should be explicitly de-
scribed. Outcomes of symptoms (e.g., pain), overall improve-
ment or satisfaction with treatment, function (e.g., back spe-
cific functional status), well being (e.g., quality of life),
disability (e.g., activities of daily living, work absenteeism), and
side effects should always be included in a systematic review of
back pain if they are reported in the original trials. Timing of
outcome measures should be explicitly described, that is, mea-
surement of outcomes less than 3 months after randomization
(short-term follow-up), between 3 months and 1 year (interme-
diate follow-up), or 1 year or more (long-term follow-up).
For examples of descriptions of inclusion criteria, see the
1997 BRG method guidelines4 or published Cochrane reviews.
Further Guidance
Study Design. Description of funding sources and potential
conflict of interest of authors of trials is recommended.
Outcomes. Outcomes of physical examination (range of
motion, spinal flexibility, degrees of straight leg raising, or
muscle strength), other symptoms (medication use, health care
utilization), and economic outcomes may be included where
appropriate, considering the aim of the intervention at issue.
Depending on the intervention specific outcomes may be rele-
vant, for example depression for a review of antidepressants.
Language. The empirical evidence on exclusion of trials
published in other languages than English is conflicting. Some
authors suggested that it might be associated with bias,14–16
whereas others showed that it has generally little effect on sum-
mary treatment effect estimates.17,18 Inclusion of studies pub-
lished in other languages than English is recommended, al-
though we acknowledge that it may not always be feasible and
may depend on the time and resources available. If trials pub-
lished in other languages are excluded from the review, the
reason for this decision should be given. The BRG strongly
recommends having an international group of (co)authors with
different language skills involved in a systematic review to en-
able including more languages than English. This is particularly
recommended on topics where there are likely to be a signifi-
cant number of non-English language publications (for exam-
ple, the Asian literature on acupuncture); we recommend in-
volving a collaborator with relevant language skills.
Methodologic Quality
Minimum Criteria. The methodologic quality of the studies
should be independently assessed by at least two reviewers.
Currently, there is empirical evidence that inadequate con-
cealment of treatment allocation19–22 and inadequate double-
blinding (of patients and outcome assessors)20 are associated
with bias. There is no evidence for any of the other method-
ologic criteria.22 Furthermore, this evidence is collected in
other fields than back pain, and it is still unclear whether this
evidence is also valid for back pain studies.
The Editorial Board of the BRG strongly recommends in-
cluding the following quality items: concealment of treatment
allocation, dropout rate, blinding of patients, blinding of out-
come assessor, and intention-to-treat analysis. The operation-
alization of the criteria should be described explicitly (for ex-
ample, Table 3), and the criteria should be scored as positive,
negative or unclear (“yes,” “no,” and “don’t know”).
Further Guidance. Some empirical evidence has been pro-
vided that blinded assessment of the methodologic quality of
trials, that is, removing authors, institution, and journal from
copies when assessing the methodologic quality, resulted in
lower and more consistent scores than open assessment.23
However, two other studies did not find an association between
blinded assessment of studies and bias.24,25 It is difficult to
achieve true blinding, because experts are usually involved in
the assessment of the methodologic quality of the studies.
Therefore, the BRG leaves it to the discretion of the reviewers
to perform a blinded quality assessment or not. Because the
quality assessment of content experts may be biased by prior
opinions, it may be desirable to have both a clinical content
expert and a nonexpert (but with a methodologic background)
assess the quality of the studies. In systematic reviews where
there is likely to be a conflict of interest (e.g., chiropractors
reviewing spinal manipulation, or physiotherapists reviewing
exercise therapy), it may be desirable to additionally mask the
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studies also for results and conclusions or to include as a re-
viewer someone who has no conflict of interest in the assess-
ment of the quality of the studies. Also, if one of the reviewers
is a/an (co)author of one of the included trials, this person
should not be involved in the quality assessment of the trial at
issue.
We recommend that reviewers pilot-test the methodologic
quality assessment on some similar articles (regarding another
intervention or disorder) that will not be included in the review.
It is important for reviewers to agree on a common interpreta-
tion of the items and their operationalization.
We recommend using a consensus method to discuss and
solve the disagreements between the reviewers. If disagreement
persists, an additional independent person should be consulted
who is an expert in review methodology. The initial interob-
server reliability (e.g., Kappa) of the quality assessment may be
evaluated and reported.
A recent study in the field of rheumatology showed that
some trials that inadequately reported the method of random-
ization and allocation concealment had actually been per-
formed adequately.26 Therefore, if the article does not contain
information on (one or more of) the methodologic criteria, the
authors may be contacted for additional information. If the
authors cannot be contacted or if the information is no longer
available, the criteria should be scored as “unclear.” If many
studies are scored as “unclear” for the same criterion, the re-
viewers could consider dropping that criterion post hoc (Chap-
ter 6 of the Cochrane Handbook).13
We recommend using the list presented in Table 4 and the
operationalization presented in Table 3. These criteria have
already been used in a number of systematic reviews within the
BRG. Compared to the 1997 method guidelines, this list in-
cludes only the internal validity criteria (n  11) that refer to
characteristics of the study that might be related to selection
bias (criteria a and b), performance bias (criteria d, e, g, and h),
attrition bias (criteria i and k) and detection bias (criteria f and
j). The internal validity criteria should be used to define meth-
odologic quality in the meta-analysis. Some recent evidence
suggests that using a different summary quality score may lead
to a different interpretation in systematic reviews.27 Therefore,
the impact of individual internal validity criteria on the overall
effect estimate should be evaluated if possible. Unfortunately,
this will often not be the case as statistical pooling (in sub-
groups) is usually not feasible in back pain reviews.
Differences in methodologic quality may explain variation
in the results of the studies included in a systematic review and
can result in over- or underestimation of the effectiveness of the
intervention at issue. However, there are no strict guidelines for
the use of methodologic quality assessment in systematic re-
views. In general, the BRG recommends choosing from the
options listed below and clearly describing the reasoning be-
hind the choice.28–30 First, the methodologic quality can be
used as an additional criterion for inclusion of studies in the
review based on one or more items (e.g., only inclusion of
RCTs or double-blind RCTs) or based on a summary quality
score (e.g., only studies that adequately fulfill 50% or more or
6 out of 11 of the validity criteria). Choosing cut-off points for
inclusion or exclusion of studies remains arbitrary. Second, a
stratified analysis can be performed in which the results are
separately presented for different strata of studies (e.g., studies
Table 3. Operationalization of the Criteria List
A A random (unpredictable) assignment sequence. Examples of adequate methods are computer generated random number table and use of
sealed opaque envelopes. Methods of allocation using date of birth, date of admission, hospital numbers, or alternation should not be
regarded as appropriate.
B Assignment generated by an independent person not responsible for determining the eligibility of the patients. This person has no information
about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the patient.
C In order to receive a “yes,” groups have to be similar at baseline regarding demographic factors, duration and severity of complaints,
percentage of patients with neurologic symptoms, and value of main outcome measure(s).
D The reviewer determines if enough information about the blinding is given in order to score a “yes.”
E The reviewer determines if enough information about the blinding is given in order to score a “yes.”
F The reviewer determines if enough information about the blinding is given in order to score a “yes.”
G Cointerventions should either be avoided in the trial design or similar between the index and control groups.
H The reviewer determines if the compliance to the interventions is acceptable, based on the reported intensity, duration, number and frequency
of sessions for both the index intervention and control intervention(s).
I The number of participants who were included in the study but did not complete the observation period or were not included in the analysis
must be described and reasons given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term follow-up and
30% for long-term follow-up and does not lead to substantial bias a “yes” is scored. (N.B. these percentages are arbitrary, not supported by
literature).
J Timing of outcome assessment should be identical for all intervention groups and for all important outcome assessments.
K All randomized patients are reported/analyzed in the group they were allocated to by randomization for the most important moments of effect
measurement (minus missing values) irrespective of noncompliance and cointerventions.
Table 4. Criteria List for the Methodological Quality Assessment
A Was the method of randomization adequate? Yes/No/Don’t know
B Was the treatment allocation concealed? Yes/No/Don’t know
C Were the groups similar at baseline regarding the most important prognostic indicators? Yes/No/Don’t know
D Was the patient blinded to the intervention? Yes/No/Don’t know
E Was the care provider blinded to the intervention? Yes/No/Don’t know
F Was the outcome assessor blinded to the intervention? Yes/No/Don’t know
G Were cointerventions avoided or similar? Yes/No/Don’t know
H Was the compliance acceptable in all groups? Yes/No/Don’t know
I Was the drop-out rate described and acceptable? Yes/No/Don’t know
J Was the timing of the outcome assessment in all groups similar? Yes/No/Don’t know
K Did the analysis include an intention-to-treat analysis? Yes/No/Don’t know
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that do or do not meet a specific quality item or low and high
methodologic quality studies defined by a preset cut-off point
on a summary quality score). Third, a sensitivity analysis can be
performed to determine whether the overall results are the
same when studies above different methodologic cut-off points
are analyzed. Fourth, weights can be applied in the analysis to
studies according to the methodologic quality, so that studies
of higher quality have more impact on the overall results. Ob-
viously, choosing weights involves additional arbitrary deci-
sions. Fifth, a cumulative meta-analysis can be performed by
examining the impact on the overall results as studies of de-
creasing quality are included one at a time. And lastly, a meta-
regression can be performed to explore the relation between
methodologic quality items and the magnitude of effect across
studies. The first four options are also available when statistical
pooling is not feasible, the last two specifically apply to statis-
tical pooling.
Data Extraction
Minimum Criteria. At least two reviewers should indepen-
dently extract the data. The data that should be extracted and
presented in a Table with study characteristics including char-
acteristics of participants, interventions, outcomes, and results
(see Inclusion Criteria).
Further Guidance. The BRG recommends using a standard-
ized form for data extraction that will facilitate the comparison
process. It is advisable to pilot test the data extraction form to
minimize misinterpretations or later disagreements. If there are
any disagreements, consensus should be achieved by discussion
among the reviewers. If disagreements persist, an additional
independent person should be consulted. If the article does not
contain sufficient information, the authors may be contacted.
Data extraction forms will vary across different systematic
reviews, but there will also be similarities among the forms
needed for reviews on back pain. Because designing a data
extraction form is time consuming, and given the important
function of data extraction forms, it may be helpful to profit
and learn from experiences of others. Examples of data extrac-
tion forms used in reviews can be obtained at the BRG Web
site: www.cochrane.iwh.on.ca
Data Analysis
Minimum Criteria. The BRG recommends performing a
quantitative or qualitative analysis only on groups of studies
that have been judged sufficiently clinically similar to yield
meaningful results. This means reviewers should avoid group-
ing studies that are clinically heterogeneous. The comparisons
with regard to the outcomes and subgroups that will be ana-
lyzed should relate directly to the objective or research ques-
tion(s) of the review. The analysis should include an explicit
description of the comparisons (Table 5).
As in every empirical study, statistical methods can be used
to analyze and summarize the data in a systematic review. The
objective of most systematic reviews will be to provide a reli-
able estimate of the effects of an intervention in comparison
with alternatives for clinically relevant subgroups of studies.
There is consensus among the Editorial Board of the BRG that
if relevant, valid data are lacking (data are too sparse or of
inadequate quality) or if data are statistically too heteroge-
neous (and the heterogeneity cannot be explained), statistical
pooling (meta-analysis) should be avoided and reviewers
should perform a qualitative analysis. In these instances, a
qualitative analysis may be performed by attributing various
levels of evidence to the effectiveness of a treatment, taking into
account the participants, interventions, outcomes, and meth-
odologic quality of the original studies. Also, if only a subset of
available trials provide sufficient data for inclusion in a meta-
analysis (e.g., some trials do not report standard deviations
[SDs]), both a quantitative and qualitative analysis could be
used in addition to each other. Because various approaches are
possible in analyzing the data in a systematic review, we suggest
that authors clearly outline the reasoning behind the approach
they use.
Further Guidance. The Editorial Board of the BRG suggests
referring to the recommendations of Chapter 8 of the Cochrane
Handbook for further guidance on data-analysis.13
Quantitative Analysis. If it is clinically relevant and statisti-
cally justified to combine the results, statistical pooling should
be performed that provides an overall effect estimate, with a
95% confidence interval for each comparison.31,32 The BRG
recommends contacting a statistician before performing a
quantitative analysis. A meta-analysis should start with exam-
ining potential publication and other biases by a funnel plot
exploring asymmetry among trial results.33 If asymmetry is
present, potential reasons should be explored. However, funnel
plots may be misleading and should be interpreted cautious-
ly.34 Formal statistical tests also exist, but there is no consensus
regarding the strengths and weaknesses of these tests.33,35
For the meta-analysis of dichotomous outcomes, the relative
risk, risk difference, or odds ratio can be used to summarize the
effect. Empirical evidence from 125 meta-analyses showed that
Table 5. Example of an Analysis for a Systematic
Review on Traction for Low Back Pain
Subgroup 1: Acute low back pain without neurological symptoms
Comparison 1.1: traction vs. placebo/sham/no treatment











Comparison 1.2: traction vs. active treatments















Subgroup 3: Chronic low back pain without neurological symptoms
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summary odds ratios and risk differences usually lead to similar
conclusions about treatment effect, but that risk differences are
substantially more heterogeneous.36 For continuous outcomes,
mean differences from each trial can be combined. If the con-
tinuous outcomes are not directly combinable—that is, if dif-
ferent instruments are used for the outcome measurements—
standardized mean differences (effect sizes) might be used.31,32
If necessary, the authors of the original studies may be con-
tacted to provide relevant information.
There are two statistical models for combining data in a
meta-analysis: the fixed effects model and the random effects
model.31 Although there are arguments favoring each model, in
general, the clinical heterogeneity of the back pain literature
suggests that the assumptions underlying the random effects
model are better suited to statistical combinations of different
trials in this field. However, the random effects model does not
account for the heterogeneity, does not explain it, and does not
take it away. Careful analysis of heterogeneity, that is, of study
characteristics that might explain differences among the results,
is always important.37 An explicit list should be given of the
characteristics of participants in, the types of interventions for,
and the exact outcome values from, each study of a group of
studies that are combined. Sensitivity analyses should be per-
formed to examine the impact of variation in summary validity
scores or individual validity items (see Methodologic Quality
section).
It may be difficult sometimes for reviewers to decide whether
it is clinically relevant to combine the results of a group of
studies in a meta-analysis—for example, studies of patients
with different types of treatments, different types of comparison
groups, or different clinical characteristics of patients studied.
There are no simple answers here, and reviewers will need to be
explicit about their decisions so that others may judge for them-
selves whether these choices were clinically sensible. A related
but separate issue concerns statistical homogeneity. A test for
the statistical homogeneity of studies may be performed to
evaluate whether the differences among the results of the stud-
ies are greater than by chance alone (Cochrane Handbook,
Chapter 8.3).13 However, the test is not very powerful, and
failure to reject the hypothesis of homogeneity is not proof that
the studies are homogeneous. If the hypothesis of homogeneity
is rejected, or if the reviewers decide, on clinical grounds, that
the studies are too heterogeneous to support statistical combi-
nations, then the potential sources of heterogeneity should be
examined because the observed differences might be caused by
factors other than chance, such as differences in methodologic
quality, characteristics of participants, interventions, control
groups, or outcomes.38 If the heterogeneity can be explained,
reviewers should separately present the results of the relevant
subgroups at issue. The subgroup analyses should be kept to a
minimum and should be defined a priori, because subgroup
analyses can be informative but also misleading.39,40 If the
heterogeneity cannot be explained, reviewers should perform a
qualitative analysis (see Minimum Criteria).
Qualitative Analysis. Although no empirical evidence exists
that supports the methods of qualitative analysis, most of the
21 completed reviews that have been published in the Cochrane
Library (issue #3, 2002) included some type of qualitative anal-
ysis. The methods used varied, and the consensus among the
BRG is that more consistency is needed.
A qualitative analysis is not similar to “vote counting,”
which involves comparing the number of studies with a positive
outcome and a negative outcome. In general, vote counting
should be avoided. A qualitative analysis consists of using var-
ious levels of evidence (Table 6) regarding the effectiveness of a
treatment, taking into account the participants, interventions,
controls, outcomes, and methodologic quality of the original
studies. Clinical homogeneity should also be a prerequisite for
a qualitative analysis, and the same structured approach should
be applied to a qualitative analysis as is applied to a quantita-
tive analysis.
Clinical Relevance
Further Guidance. The BRG recommends including an as-
sessment of clinical relevance of study results in systematic
reviews. The conclusions regarding the effectiveness of the in-
tervention should contain all the important information to en-
able users to make a decision if the results apply to their pop-
ulation. The clinical relevance of the studies should be
independently assessed by at least two reviewers. The following
five questions are recommended. They are based on previous
guides to critical reading of the medical literature41,42 and two
systematic reviews on back pain43,44:
1. Are the patients described in detail so that you can decide
whether they are comparable to those that you see in your
practice?
2. Are the interventions and treatment settings described
well enough so that you can provide the same for your
patients?
3. Were all clinically relevant outcomes measured and
reported?
4. Is the size of the effect clinically important?
5. Are the likely treatment benefits worth the potential
harms?
Reporting of Results and Conclusions
Further Guidance. The BRG noticed that there is wide vari-
ation among reviews published in their module of the Cochrane
Library (issue #4, 2002) with regard to the style they use to
report results and conclusions. This further guidance is in-
tended to increase consistency among future reviews and up-
dates of reviews.
The reporting of results in the text of reviews should contain
the following items (Table 7): the intervention, the type of
patients, the comparison group, the number of trials (number
of patients), results of quantitative analysis (effect size plus
confidence interval [CI]), results of qualitative analysis (level of
evidence, direction of the effect [more effective, no difference]),
the outcome measures, and the timing (short-term or long-
term) of the outcome measure.
Table 6. Levels of Evidence
Strong—consistent findings among multiple high quality RCTs*
Moderate—consistent findings among multiple low quality RCTs and/or
CCTs and/or one high quality RCT
Limited—one low quality RCT and/or CCT
Conflicting—inconsistent findings among multiple trials (RCTs and/or
CCTs)
No evidence from trials—no RCTs or CCTs
Consistency and quality should be clearly defined a priori
* There is consensus among the Editorial Board of the BRG that strong
evidence can only be provided by multiple high quality trials that replicate
findings of other researchers in other settings.
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Examples are:
1. The pooled analysis of 7 trials (1268 people) shows that
behavioral treatment is more effective than no treatment for
patients with chronic back pain without neurologic symp-
toms on short-term pain relief with standardized mean dif-
ference (SMD) 0.62 (95% CI 0.25 to 0.98) and short-term
behavioral outcomes with SMD 0.40 (95% CI 0.10 to
0.70).
2. There is limited evidence (4 trials; 354 people) that there
is no difference in short-term pain relief between acupunc-
ture and placebo or sham acupuncture for patients with
chronic back pain with or without neurologic symptoms.
Discussion
The Editorial Board of the BRG believes that systematic
reviews represent one of the key advances in medical
science in the past 10 years and offer the real opportunity
to lead to changes in medical practice worldwide. Obvi-
ously, one of the major challenges for the future is to
increase implementation of the results of systematic re-
views. Some initiatives have been developed that try to
make systematic reviews more easily available for clini-
cians in daily practice. Recently published clinical guide-
lines on the management of low back pain have used the
evidence from systematic reviews as basis for their rec-
ommendations.45 Also, the BMJ Publishing Group has
issued “Clinical Evidence,” which is a summary of the
current state of knowledge based on Cochrane and other
systematic reviews on prevention and treatment of a wide
range of clinical conditions (www.clinicalevidence.com).
Whether these and other implementation efforts indeed re-
sult in a change in clinicians’ behavior and in improved
patient outcomes remains unclear.
Systematic reviews need to be conducted as carefully
as the trials they report and, to achieve full impact, sys-
tematic reviews need to meet high methodologic stan-
dards. The objective of these method guidelines is to help
reviewers to design, conduct, and report reviews of trials
in the field of back pain systematically and explicitly.
These guidelines are not intended to set a gold standard
or to discourage people from doing a systematic review.
On the contrary, we encourage people to undertake a
systematic review in collaboration with others. For more
guidance on systematic reviews of back pain, we recom-
mend referring to the Cochrane Handbook or looking at
the Web site of the BRG: www.cochrane.iwh.on.ca. Ad-
dress: Cochrane Collaboration Back Review Group, In-
stitute for Work & Health, Toronto, Ontario, Canada,
M5G 2E9. Telephone: (416) 927-2027; fax: (416)
927-4167.
Key Points
● Many reviews of therapeutic interventions for
spinal disorders have been published. It is impor-
tant that these reviews use adequate, systematic
methods to avoid bias.
● Previous method guidelines for systematic re-
views in the field of spinal disorders were updated.
● These method guidelines include recommenda-
tions that are mandatory (minimum criteria) and
optional (further guidance) for reviewers conduct-
ing reviews within the Cochrane Collaboration
Back Review Group.
● Others may find them useful to plan, conduct, or
evaluate systematic reviews in the field of spinal
disorders.
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